Assembly Biosciences Inc (NASDAQ:ASMB) Forecasted to Post Q3 2019 Earnings of ($0.97) Per Share

Assembly Biosciences Inc (NASDAQ:ASMB) – Stock analysts at Svb Leerink lifted their Q3 2019 EPS estimates for Assembly Biosciences in a report released on Tuesday, August 6th, according to Zacks Investment Research. Svb Leerink analyst G. Porges now forecasts that the biopharmaceutical company will post earnings per share of ($0.97) for the quarter, up from their previous estimate of ($1.19). Svb Leerink also issued estimates for Assembly Biosciences’ Q4 2019 earnings at ($0.89) EPS, FY2019 earnings at ($3.63) EPS, FY2020 earnings at ($4.98) EPS, FY2021 earnings at ($5.71) EPS and FY2022 earnings at ($3.89) EPS.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.41. Assembly Biosciences had a negative net margin of 622.25% and a negative return on equity of 46.33%. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.90 million.

Several other research firms have also commented on ASMB. BidaskClub upgraded shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 6th. Zacks Investment Research lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday. William Blair reiterated a “buy” rating on shares of Assembly Biosciences in a research note on Tuesday, July 16th. ValuEngine upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Chardan Capital reiterated a “hold” rating and set a $30.00 price objective on shares of Assembly Biosciences in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $33.25.

ASMB stock opened at $12.28 on Thursday. The company has a current ratio of 9.20, a quick ratio of 9.20 and a debt-to-equity ratio of 0.06. The stock has a market cap of $329.11 million, a PE ratio of -3.09 and a beta of 1.44. The company has a 50-day moving average price of $13.28 and a 200 day moving average price of $16.76. Assembly Biosciences has a 12 month low of $11.49 and a 12 month high of $41.00.

A number of large investors have recently added to or reduced their stakes in ASMB. Bank of Montreal Can boosted its holdings in Assembly Biosciences by 2,084.1% during the second quarter. Bank of Montreal Can now owns 1,922 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 1,834 shares in the last quarter. Quantamental Technologies LLC raised its position in Assembly Biosciences by 16,941.2% during the second quarter. Quantamental Technologies LLC now owns 2,897 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 2,880 shares during the period. Aperio Group LLC acquired a new position in Assembly Biosciences during the second quarter worth $55,000. Tower Research Capital LLC TRC raised its position in Assembly Biosciences by 9,134.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,340 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,293 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in Assembly Biosciences by 87,340.0% during the first quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 4,367 shares during the period. 85.82% of the stock is currently owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Recommended Story: Real Estate Investment Trust (REIT) ETF

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.